Eli Lilly invested directly and through its Lilly Asia Ventures fund, in a round that brought liver disease-focused drug developer Terns' overall funding to $197m.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Utec has made its largest initial commitment to date by backing Keio-founded Metcela, a developer of cell therapies for heart disease.

SK Biopharmaceuticals will divest a 12% stake in Arvelle, which is looking to commercialise an epilepsy drug treatment, through the acquisition.

Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.

The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.

Ionis Pharmaceuticals and Johnson & Johnson Innovation – JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA conjugate medicines.

The Alphabet, GSK, WuXi AppTec, Johnson & Johnson, Roche and Illumina-backed genetic testing service has now raised over $870m altogether.